Browse studies
Find your next paid study
52 recruiting studies matching your filters
Phase 1
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed…
Solid Tumor, AdultMicrosatellite Stable Colorectal CancerHead and Neck Squamous Cell Carcinoma+10 more
Estimated
~$10 – $8,750
KaliVir ImmunotherapeuticsNCT06444815
Personalized Models for Cancer Research
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate cancer research ranging from disease mechanisms to perso…
Solid Tumor, Adult
Estimated
~$10 – $750
New York Stem Cell Foundation Research InstituteNCT06350539
Phase 1
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination …
CancerSolid Tumor, AdultCancer Metastatic+3 more
Estimated
~$10 – $8,750
Shenzhen Ionova Life Sciences Co., Ltd.NCT04443088
Phase 1
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of…
OncologyMEK MutationRAF Gene Mutation+6 more
Estimated
~$10 – $8,750
Nested Therapeutics, IncNCT06326411